Statins and the neuromuscular system: a neurologist's perspective

Area of Science:

• Neurology
• Pharmacology
• Genetics

Background:

• Statin intolerance, primarily manifesting as neuromuscular side effects, poses a challenge to cardiovascular disease prevention.
• The significant cardiovascular benefits of statins are hindered by under-recognized or controversial adverse effects.
• Current understanding and management strategies for statin-induced myopathy require further development.

Purpose of the Study:

• To review recent advancements in understanding statin intolerance.
• To highlight the limitations in the current definition and presentation of statin myopathy.
• To emphasize the need for improved management, prevention, and genetic risk factor identification.

Main Methods:

• Literature review of recent developments in statin intolerance and myopathy.
• Analysis of clinical definitions and presentations of statin-induced neuromuscular side effects.
• Discussion of current management and prevention strategies.

Main Results:

• Existing clinical definitions of statin myopathy are inadequate for myological assessment.
• Validated management and prevention protocols for statin intolerance are lacking.
• Identification of genetic risk factors for statin myopathy requires further investigation.

Conclusions:

• Neurologists should play a more active role in evaluating and managing statin intolerance.
• Enhanced understanding of genetic predispositions is necessary for personalized statin therapy.
• Improved diagnostic criteria and therapeutic strategies are needed to address statin-induced neuromuscular issues.